H.C. Wainwright Thinks MEI Pharma’s Stock is Going to Recover

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on MEI Pharma (MEIPResearch Report) today and set a price target of $10.00. The company’s shares closed last Monday at $2.02, close to its 52-week low of $1.68.

According to, Fein is ranked 0 out of 5 stars with an average return of -4.3% and a 33.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals, Inc., and Global Blood Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MEI Pharma with a $11.20 average price target, a 480.3% upside from current levels. In a report issued on February 3, Jefferies also initiated coverage with a Buy rating on the stock with a $4.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $4.29 and a one-year low of $1.68. Currently, MEI Pharma has an average volume of 1.67M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Read More on MEIP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More